Spesolimab is an interleukin-36 (IL-36) receptor antagonist. It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares. Spesolimab works...
Spesolimab is indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults.
Aalborg Sygehus Syd, Aalborg, Denmark
Odense University Hospital, Odense, Denmark
Hospital Puerta de Hierro, Majadahonda, Spain
Inje University Busan Paik Hospital, Busan, Korea, Republic of
Addenbrooke's Hospital, Cambridge, United Kingdom
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany
UZ Leuven, Leuven, Belgium
Hospital Sultanah Aminah, Johor Bahru, Malaysia
HOP Saint-Louis, Paris, France
Pusan National Univ. Hosp, Busan, Korea, Republic of
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.